Director/PDMR Shareholding

RNS Number : 7550X

AstraZeneca PLC

01 May 2019

 

1 May 2019 12:00 BST

Transactions by Persons Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 29 and 30 April 2019, it was notified of transactions in the Company's ordinary shares of $0.25 each (Ordinary Shares) and American Depositary Shares (ADSs) by certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) as set out below. Two ADSs are equivalent to one Ordinary Share.

PDMR	Position	Nature of the transaction	Quantity	Price
Pascal Soriot	Chief Executive Officer	Purchase of Ordinary Shares	17,100	GB£58.255
Philip Broadley	Non-Executive Director	Purchase of Ordinary Shares	520	GB£57.38
Sheri McCoy	Non-Executive Director	Purchase of ADSs	2,372	US$38.1783
Sheri McCoy	Non-Executive Director	Purchase of ADSs	100	US$38.172
Deborah DiSanzo	Non-Executive Director	Purchase of ADSs	1,000	US$38.3056

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Pascal Soriot
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) GB£58.255 17,100
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	29 April 2019
f)	Place of the transaction	XLON

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Philip Broadley
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) GB£57.38 520
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	30 April 2019
f)	Place of the transaction	XLON

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sheri McCoy
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depositary Shares CUSIP: 046353108
b)	Nature of the transaction	Purchase of AstraZeneca PLC American Depositary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) US$38.1783 2,372 US$38.175 100
d)	Aggregated information - Aggregated volume - Price	2,472 US$38.178
e)	Date of the transaction	29 April 2019
f)	Place of the transaction	NYSE

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Deborah DiSanzo
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	AstraZeneca PLC American Depositary Shares CUSIP: 046353108
b)	Nature of the transaction	Purchase of AstraZeneca PLC American Depositary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) US$38.3056 1,000
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	29 April 2019
f)	Place of the transaction	NYSE

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in its main therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Gonzalo Viña	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Matt Kent	UK/Global	[phone]
Jennifer Hursit	UK/Global	[phone]
Christina M Hägerstrand	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Henry Wheeler	Oncology	[phone]
Christer Gruvris	BioPharma - Cardiovascular; Metabolism	[phone]
Nick Stone	BioPharma - Respiratory; Renal	[phone]
Josie Afolabi	Other	[phone]
Craig Marks	Finance; Fixed Income	[phone]
Jennifer Kretzmann	Retail Investors; Corporate Access	[phone]
US toll-free		[phone]

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

END

 

 

DSHUAURRKWAVRAR